Ardelyx develops novel, first-in-class oral therapeutics to correct mineral metabolism and metabolic disorders. The Company's molecules, whose systemic exposure is severely restricted, target transporters and receptors, modulating the uptake of nutrients or inducing secretion of key hormones to produce a therapeutic benefit in patients. Its non-systemic products act from within the intestines to avoid potential side effects that could occur with systemic exposure.
Ardelyx lead product, RDX5791, a minimally-absorbed, orally administered NHE3 sodium transport inhibitor, is being developed both for constipation-predominant irritable bowel syndrome (IBS-C) and for prevention of excess dietary sodium absorption, a new treatment modality for high blood pressure. RDX5791 is in phase 2 for IBS-C and a dose-ranging/regimen study for inhibition of excess dietary sodium absorption. Ardelyx is also developing RDX002, a minimally-absorbed, orally administered NaP2b phosphate transport inhibitor for the inhibition of phosphate absorption in patients with chronic kidney disease, and RDX009, a minimally-absorbed, orally administered TGR5 agonist for the treatment of type 2 diabetes through direct induction of intestinal incretins such as GLP-1 and PYY. 

Show more
Type
Public
HQ
Fremont, US
Founded
2007
Size (employees)
93 (est)
Ardelyx was founded in 2007 and is headquartered in Fremont, US
Report incorrect company information

Key People/Management at Ardelyx

Mike Raab

Mike Raab

President and Chief Executive Officer
Mark Kaufmann

Mark Kaufmann

Chief Financial Officer
MBBS Reg Seeto

MBBS Reg Seeto

Chief Operating Officer
Jeremy Caldwell

Jeremy Caldwell

Chief Scientific Officer
Elizabeth Grammer

Elizabeth Grammer

Senior Vice President and General Counsel
Jeff Jacobs

Jeff Jacobs

Senior Vice President, Technical Operations
Show more

Ardelyx Office Locations

Ardelyx has an office in Fremont
Fremont, US (HQ)
34175 Ardenwood Blvd
Show all (1)
Report incorrect company information

Ardelyx Financials and Metrics

Ardelyx Financials

Ardelyx's revenue was reported to be $42 m in FY, 2017
USD

Revenue (FY, 2017)

42 m

Gross profit (FY, 2017)

33.6 m

Gross profit margin (FY, 2017), %

80%

Net income (FY, 2017)

(64.3 m)

EBIT (FY, 2017)

(65.1 m)

Market capitalization (20-Apr-2018)

229.4 m

Cash (31-Dec-2017)

75.4 m
Ardelyx's current market capitalization is $229.4 m.
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017

Revenue

24 m24 m42 m

Revenue growth, %

Cost of goods sold

8.4 m

Gross profit

33.6 m
Quarterly
USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Revenue

18.1 m7.6 m5.9 m18.1 m

General and administrative expense

2.9 m3.4 m4.3 m4.9 m4.3 m6 m5.8 m

R&D expense

6.2 m14.7 m19.3 m23.8 m24.9 m22.4 m20.6 m

Operating expense total

9.1 m18.1 m23.5 m28.7 m29.2 m28.4 m26.4 m21.2 m
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017

Cash

107.3 m107 m74.6 m75.4 m

Accounts Receivable

2.6 m2.6 m10.8 m

Inventories

1.2 m5 m3.2 m

Current Assets

111.1 m112 m204 m149.7 m
Quarterly
USDQ1, 2017Q2, 2017Q3, 2017

Cash

71.2 m63.6 m59.5 m

Inventories

4.3 m

Current Assets

178 m153.9 m133.6 m

PP&E

8.9 m9.3 m
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(3.2 m)(29.6 m)(112.4 m)(64.3 m)

Depreciation and Amortization

302 k829 k1.3 m2.6 m

Inventories

(2.3 m)

Accounts Payable

831 k(371 k)2.1 m(1 m)
Quarterly
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q3, 2017

Net Income

(29 m)(28 m)(20.7 m)

Inventories

4.3 m

Accounts Payable

2.3 m1 m2.5 m2.7 m2.7 m4.9 m4.7 m6.3 m5.9 m1.7 m
USDY, 2017

Revenue/Employee

451.6 k

Financial Leverage

1.1 x
Show all financial metrics
Report incorrect company information

Ardelyx News and Updates

Irritable Bowel Syndrome Treatment Market to Surpass US$ 2,300 Million Threshold by 2025 Globally, with North America Positioned as the Growth Engine

Global Irritable Bowel Syndrome Treatment Market by Drug Type, Medical Condition, Distribution Channel and Region - Insights, Size, Share, Opportunity Analysis, and Industry Forecast till 2025 Posted via Industry Today. Follow us on Twitter @IndustryToday
Report incorrect company information